J. Gaudreault, D. Fei, J. C. Beyer, A. Ryan, L. Rangell, V. Shiu, L. A. Damico, “Pharmacokinetics and Retinal Distribution of Ranibizumab, a Humanized Antibody Fragment Directed against VEGF-A, Following Intravitreal Administration in Rabbits,” Retina, Vol. 27, No. 9, 2007, pp. 1260-1266. doi:10.1097/IAE.0b013e318134eecd

has been cited by the following article:

• TITLE: Three Consecutive Monthly Intravitreal Ranibizumab for Choroidal Neovascularization in Central Serous Choriorethinopathy: A Case Report

  AUTHORS: Kazim Erol, Esin Sogutlu Sari, Arif Koytak, A Karaçor, D. T. Çoban, M. Bulut

  KEYWORDS: Central Serous Choriorethinopathy; Choroidal Neovascularization; Ranibizumab

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.2 No.3, August 24, 2012

  ABSTRACT: Purpose: The author report the result of three consecutive monthly intravitreal ranibizumab injection for choroidal neovascularization (CNV) after bevacizumab injection for chronic central serous rethinopathy (CSR). Methods: A 48 year old man with chronic CSR was treated with intravitreal single dose 2.5 mg bevacizumab. One year after CNV was occurred, and three consecutive monthly intravitreal ranibizumab injections were performed. Results: Four weeks later the first ranibizumab dose, best corrected visual acuity was improved 20/80 to 20/20 and remained stable within one year. Conclusion: Repeat intravitreal ranibizumab injection in CNV after bevacizumab injection for chronic CSR appeared to be an effective treatment option.